Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Icecure Medical Ltd (OQ:ICCM)

Business Focus: Advanced Medical Equipment & Technology

Mar 27, 2024 08:30 am ET
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Overview of U.S. Commercial Strategy will be Discussed on Conference Call
Feb 27, 2024 07:00 am ET
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
Session conducted by Dr. Rupa Renganathan, who performed India's first breast cancer cryoablation procedure with ProSense®; Expert interview with Dr. Hania Bednarski, who has performed cryoablation breast procedures since 2014
Feb 26, 2024 07:00 am ET
Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 months following cryoablation
Feb 15, 2024 07:00 am ET
IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan
CAESAREA, Israel, Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced Eisuke Fukuma, MD, PhD, who has performed over 600 breast cryoablation procedures with ProSense®, will host events that feature ProSense® at two upcoming medical conferences in Japan. Dr. Fukuma is Chair, Breast Center, Kameda Medical Center, and President of the 8th International Oncoplastic Breast Surgery S
Jan 30, 2024 07:00 am ET
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer
IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of previous expectation
Jan 29, 2024 07:00 am ET
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
IceCure exhibits and provides hands-on demonstrations at SIO 2024 Annual Meeting in California, receiving enthusiastic response from interventional oncologistsICE3 trial data were central to the Breast Cryoablation Master Class taught by several ProSense® users, including Dr. Tomkovich, ICE3's Co- Principal Investigator, and Dr. Fine, ICE3 Investigator who has treated numerous participantsCAESAREA, Israel, Jan. 29, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroy
Jan 16, 2024 07:00 am ET
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
ProSense® users speaking at the conference about cryoablation included ISVIR President Dr. Suyash Kulkarni, as well as Dr. Shuvro Roy-Choudhury
Jan 12, 2024 04:05 pm ET
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it...
Jan 10, 2024 07:00 am ET
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
U.S. sales continue to increase with 25% jump in ProSense® system and disposable probe sales in 2023 over prior yearICE3 study is set for completion and final data read outCAESAREA, Israel, Jan. 10, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today issued the following letter to its shareholders from its Chief Executive Officer, Eyal Shamir.
Jan 03, 2024 07:00 am ET
New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
Independent mouse study conducted at Case Western Reserve University School of Medicine, published in OncoImmunology, builds on body of evidence demonstrating cryoablation can activate the body's natural immune response by enhancing CD8+ T cells, which are an important arm of immune responseData support previous studies and suggest ProSense® may produce anti-cancer benefits in humans beyond tumor destruction during cryoablation procedureCAESAREA, Israel, Jan. 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation tech
Dec 13, 2023 07:00 am ET
Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"
Independent study published in Annals of Surgical Oncology concludes cryoablation is an oncologically safe and feasible minimally invasive procedure option in lieu of surgery for patients with early-stage, low-risk breast cancerStudy's authors suggest the widespread use of screening mammography allows for earlier detection - and therefore increased customization of treatment, less aggressive management, reduced treatment burden, improved quality of life - and examines cryoablation as the "next step in the surgical de-escalation of breast cancer"Study suggests that cryoablation provides a sig
Nov 29, 2023 07:00 am ET
IceCure's ProSense® Deepens Regulatory Approval in India
ProSense® is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulationsBreast cancer cryoablation is already performed in India with ProSense®CAESAREA, Israel, Nov. 29, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the Central Drugs Standard Control Organization ("CDSCO") in India has g
Nov 28, 2023 07:00 am ET
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
Independent study concluded:- IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100%- 92.4% of patients (N= 24) were discharged the day after cyroablation- The technology's ability to preserve renal function post-treatment is paramount for patients' quality of life- Findings serve as a guide for medical professionals in choosing efficient, cost-effective, and patient-friendly treatment options, thereby benefiting society at large by optimizing kidney tumor managementSuccess across multiple indi
Nov 15, 2023 07:00 am ET
IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights
ProSense® system and disposables sales continue upward trend compared to the equivalent prior year periodExpanded regulatory footprint, growing body of evidenced-based data, and distribution agreements demonstrate an increasing acceptance of minimally invasive alternatives to standard of care cancer treatmentICE3 trial remains on track and expected to be completed in the first quarter of 2024 Conference call scheduled for today at 10 am ESTCAESAREA, Israel, Nov. 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a min
Nov 15, 2023 06:30 am ET
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer
Objective is to reopen file to address comments and find appropriate comparator group that is more representative of the patient population the Company is seeking to treat with its ProSense® systemCompany seeks to complete the review process, establish special controls, and finalize classification of ProSense®CAESAREA, Israel, Nov. 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed a request for s
Nov 08, 2023 07:00 am ET
IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023
CAESAREA, Israel, Nov. 8, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2023 before the Nasdaq Stock Market opens on Wednesday, November 15, 2023 and also discuss such results and other corporate developments on a conference call at 10:
Nov 06, 2023 07:00 am ET
Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System
Independent, non-sponsored studies by doctors using ProSense® to treat cancers of the breast, lung, kidney, and musculoskeletal system, as well as endometriosis and fibroadenomasGrowing body of scientific data, including 13 breast cancer studies, is expected to drive adoptionProSense® is approved for various indications in 15 countries including the U.S., Canada, Europe, Brazil, and ChinaCAESAREA, Israel, Nov. 6, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys
Nov 03, 2023 04:00 pm ET
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
CAESAREA, Israel, Nov. 3, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), a developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it has received a written notice (the "Notice") from Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid pr
Oct 30, 2023 08:00 am ET
IceCure's ICE3 Trial Results Demonstrating 96.91% Recurrence Free Rate Featured in a Presentation at BISICON 2023 in India
ICE3 trial will be finalized in Q1 2024IceCure's distributor in India, Novomed, exhibited ProSense® and received a high level of interest from doctors, clinics, and hospitalsProSense was used to perform India's first breast cryoablation procedure in June 2023CAESAREA, Israel, Oct. 30, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 10th Annual Conference of
Oct 25, 2023 08:00 am ET
Independent Scientific Paper by Doctors Using IceCure's ProSense® Published in Journal of Breast Imaging Presents Advantages of Cryoablation Breast Conserving Over Surgery in Early Breast Cancer Patie
Paper cites IceCure's ICE3 interim clinical study results as evidence of safety and efficacy of cryoablation in early-stage breast cancer
Oct 05, 2023 08:00 am ET
Women Deemed Inoperable for Breast Cancer Benefitted from IceCure Medical's ProSense as an Independent Study Performed in Italy Showed a Tumor Reduction Rate of 93.43% to 96.81%
Disappearance of lesions and absence of residual malignant cells in Luminal-A group considered to be predictive for the complete effectiveness of the treatment This is the latest in a growing body of evidence presented by independent, non-sponsored doctors who use ProSense  CAESAREA, Israel, Oct. 5, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the findings from an independen
Oct 02, 2023 08:00 am ET
Independent Study Validates IceCure's ProSense Cryoablation is Safe & Effective Outpatient Procedure for Breast Cancer with 96.8% Success Rate
Study was conducted in Spain with women who declined standard of care surgeryProSense is approved for the treatment of breast cancer throughout the European UnionCAESAREA, Israel, Oct. 2, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that new data was presented at the European Society of Breast Imaging ("EUSOBI") Scientific Meeting in Valencia, Spain by Lucía Graña-López, MD, PhD,
Sep 22, 2023 08:00 am ET
Renowned Spanish Radiologist Lucía Graña-López to Present Data Using IceCure Medical's ProSense at European Society of Breast Imaging Scientific Meeting 2023
Growing body of evidence-based data is giving women a minimally invasive alternative to the standard of care lumpectomyPatients throughout the European Union have access to ProSense for the treatment of malignant and benign breast tumorsCAESAREA, Israel, Sept. 22, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that Lucía Graña-López, MD, PhD, a Spain-based radiologist and user of P
Sep 20, 2023 07:00 am ET
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer
CAESAREA, Israel, Sept. 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the U.S. Food and Drug Administration ("FDA") has at this time denied the Company's De Novo Classification request for breast cancer which was submitted based on interim analysis from its ICE3 study. The FDA's position on the De Novo Classification request for breast cancer has no effect on ProSense's FDA cleared authorization for
Jul 24, 2023 08:00 am ET
Health Canada Approves IceCure Medical's Minimally Invasive ProSense Cryoablation System
Strong interest in ProSense from healthcare providers in Canada strengthens market potentialProSense now approved throughout North AmericaCAESAREA, Israel, July 24, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that Health Canada, the Canadian government's regulatory agency, has approved IceCure's ProSense System, disposable cryoprobes, and introducers as cryosurgical tools for in
Jul 17, 2023 08:00 am ET
IceCure Medical Expands Distribution of ProSense® into Portugal Through Agreement with Medicinália Cormédica: Upfront Systems & Probes Sales
ProSense has CE mark of regulatory approval in the European UnionInitial purchase of 2 ProSense Systems plus disposable cryoprobes and introducers CAESAREA, Israel, July 17, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has entered a non-exclusive distribution agreement with Medicinália Cormédica – MC Medical, Lda. ("MC Medical"), the largest distributor of third-pa
Jun 13, 2023 08:00 am ET
IceCure Medical to Review Recent Progress at Maxim Group's Virtual Healthcare Conference
IceCure CEO, Eyal Shamir, to present and conduct Q&A on Wednesday, June 21st at 11:00 AM Eastern Time on Track 2
May 31, 2023 08:00 am ET
May 22, 2023 08:00 am ET
IceCure Medical Reports First Quarter 2023 Financial & Operational Results
Physician Interest and Adoption of ProSense in the U.S. Builds Momentum as ProSense is Featured at Medical Conferences and Educational CoursesProSense was the only Cryoablation System Used in a First-of-its-Kind Cryotherapy Continuing Medical Education (CME) course at the American Society of Breast Surgeons (ASBrS) 2023 Annual Meeting Where a Plan was Presented for a Proposed ASBrS Cryoablation TrialRegulatory Approval Received in China for Commercial Use of Disposable CryoprobesIndependently Conducted Endometriosis Study Shows 92.8% Efficacy in Avoiding Secondary SurgeryConference Call to b
May 15, 2023 08:00 am ET
IceCure to Report First Quarter 2023 Financial & Operational Results on
CAESAREA, Israel, May 15, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will release its financial and operational results for the three months ended March 31, 2023 with a press release prior to the market open on Monday, May 22, 2023 and will host a conference call at 10:00 a.m. ET that day to discuss the results and corporate developments.
May 01, 2023 08:00 am ET
Cryoablation Takes Center Stage at American Society of Breast Surgeons' 24th Annual Meeting
IceCure's ProSense was the cryoablation system used in first-of-its-kind cryotherapy continuing medical education (CME) courseHigh level of interest expressed in cryoablation from attending surgeons and from American Society of Breast Surgeons (ASBrS) leadershipPlan presented for a proposed ASBrS Cryoablation trial during CME courseCAESAREA, Israel, May 1, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today annou
Apr 24, 2023 08:00 am ET
IceCure Medical to Provide Educational Support in a First-of-its-Kind Cryotherapy Course at the American Society of Breast Surgeons' 24th Annual Meeting
Physicians Attending the CME Course to Demo ProSense, Learn More About Breast Cryoablation, and Receive Hands-on Training Previously Published ICE3 Trial Interim Results will be Highlighted to Further Raise Awareness of Breast CryoablationCAESAREA, Israel, April 24, 2023 IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its educational support for a continuing medical education (CME) course on cryotherapy at the American
Apr 20, 2023 08:00 am ET
IceCure's ProSense System Used in Endometriosis Cryoablation Study That Demonstrated Efficacy Rate of 92.8% to Avoid Secondary Surgery
ProSense System among the two types of systems used in the studyPain-free survival rates of 93.75% at 6 months and 82.72% at 36 months post-procedure190 million women globally live with endometriosis, for which there is no cure; current treatments aim to control symptoms Data presented at Society of Interventional Radiology 2023 Annual Scientific Meeting by lead investigator Francois H. Cornelis, MD, PhDCAESAREA, Israel, April 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys
Apr 19, 2023 08:00 am ET
IceCure Medical Ordinary Shares to Trade Exclusively on Nasdaq: Company to Voluntarily Delist Shares from Trading on the Tel Aviv Stock Exchange
CAESAREA, Israel , April 19, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announces that it has initiated a process to voluntarily delist its ordinary shares, no par value per share (the "Ordinary Shares"), from the Tel Aviv Stock Exchange (the "TASE").
Mar 29, 2023 08:00 am ET
IceCure Medical Reports 2022 Full Year Financial Results & Recent Corporate Developments; Milestone Achievements Expected to Drive Revenue Growth in 2023
Rising Utilization of ProSense in the U.S. Market Generates Year-over-Year Consumable Revenue GrowthPhysician Adoption Continues to Grow Ahead of the FDA's Response to the Company's Application for Marketing Approval in Breast Cancer IndicationRegulatory Approval Received in China for Commercial Use of IceSense3 Disposable Cryoprobes, to be Used in Combination with its IceSense3 Cryoablation System Console, Which was Previously Approved in ChinaCryoablation System and Cryoprobes to be Sold in China Through Exclusive Distribution PartnershipConference Call to be Held Today at 10:00 am Eastern
Mar 28, 2023 08:00 am ET
IceCure Medical Receives Regulatory Approval in China for Commercial Use of its IceSense3 Disposable Cryoprobes
This approval allows the use of the IceSense3 disposable cryoprobes in combination with the Company's IceSense3 console, which was previously approved by the NMPAProducts to be distributed in China through agreement with Shanghai Medtronic Zhikang Medical Devices Co. Ltd., an affiliate of Medtronic plc, and Beijing Turing Medical Technology Co. Ltd.Ongoing physician awareness and education efforts will potentially accelerate market acceptance for novel technology and deliver better patient outcomes for those suffering from malignant and benign tissue of the breast, lung, bone, liver, and kid
Mar 20, 2023 08:00 am ET
IceCure Medical to Report 2022 Full Year Financial & Operational Results on March 29, 2023
CAESAREA, Israel, March 20, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, announced that it will release its full year financial and operational results for the twelve months ended December 31, 2022, prior to the market open on Wednesday, March 29, 2023,  and will host a conference call at 10:00 a.m. ET to discuss the results and corporate developments.
Feb 09, 2023 07:00 am ET
Jan 26, 2023 07:00 am ET
IceCure's ProSense Featured in Breast Session at the Society of Interventional Oncology's Annual Scientific Meeting in Washington, D.C.
Panel discussion included doctors currently using the ProSense cryoablation systemLive ProSense demonstrations conducted at IceCure's boothCAESAREA, Israel, Jan. 26, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced its participation in the Society of Interventional Oncology's Annual Scientific Meeting ("SIO2023") in Washington, D.C. on January 19 - 23, 2023. ProSense was demonstrated throughout the duration of the c
Jan 25, 2023 07:00 am ET
IceCure's ProSense Presented in Hands-On Training Course at The American Society of Breast Surgeons Breast Follows Ultrasound Course
Professional training courses are well-timed following IceCure's FDA filing for marketing authorization of ProSense with breakthrough indication
Jan 23, 2023 07:00 am ET
U.S. Patent Office Grants Notice of Allowance to IceCure for Novel Cryogenic Pump for Next-Generation Cryoablation Systems
Patent has also been granted or allowed in major markets, including the European Union and Japan Cryogenic pump potentially broadens clinical indications for IceCure's cryoablation platform technologyCAESAREA, Israel, Jan. 23, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled "Cryogen Pump". The patent wi
Jan 18, 2023 07:00 am ET
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems
Innovating as a global leader in cryoablation technologies, with 29 patents issued and allowedCryogenic pump enables multiple and longer duration procedures without the need to refill liquid nitrogen, potentially expanding clinical indicationsCAESAREA, Israel, Jan. 18, 2023 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced it has received a Notice of Allowance from the Japan Patent Office (the "JPO") for IceCure's patent
Jan 04, 2023 07:00 am ET
IceCure Medical CEO Issues Letter to Shareholders
CAESAREA, Israel, Jan. 4, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today released the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.
Dec 27, 2022 07:30 am ET
Thinking about buying stock in 180 Life Sciences, HTG Molecular, Markforged, Icecure Medical, or Rigel Pharmaceuticals?
NEW YORK, Dec. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATNF, HTGM, MKFG, ICCM, and RIGL.
Dec 23, 2022 03:00 pm ET
IceCure Medical Ltd. Announces Closing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CAESAREA, Israel, Dec. 23, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the closing of its previously announced "best efforts" public offering of 8,787,880 shares of the Company's ordinary shares (the "Ordinary Shares") priced at-the-market under Nasdaq rules at a price to the public of $1.65 per share. The gross proceeds of the offering to the Company were approximately $14.5 million, before deducting placement
Dec 23, 2022 07:53 am ET
Thinking about buying stock in ReShape Lifesciences, Exicure, Blue Apron, Coherus Biosciences, or Icecure Medical?
NEW YORK, Dec. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RSLS, XCUR, APRN, CHRS, and ICCM.
Dec 21, 2022 08:00 am ET
IceCure Medical Ltd. Announces Pricing of $14.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
CAESAREA, Israel, Dec. 21, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the pricing of its previously announced "best efforts" public offering of 8,787,880 shares of the Company's ordinary shares (the "Ordinary Shares") priced at-the-market under Nasdaq rules at a price to the public of $1.65 per share. The gross proceeds of the offering to the Company are expected to be approximately $14.5 million, before deduc
Dec 20, 2022 03:00 pm ET
IceCure Medical Ltd. Announces Proposed Public Offering
CAESAREA, Israel, Dec. 20, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the commencement of a proposed public offering of its ordinary shares. All of the securities to be sold in the offering are to be offered by IceCure. The proposed public offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Dec 20, 2022 07:36 am ET
Thinking about buying stock in SINTX Technologies, Icecure Medical, Verona Pharma, Applied UV, or Mitsubishi UFJ Financial Group?
NEW YORK, Dec. 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SINT, ICCM, VRNA, AUVI, and MUFG.
Dec 19, 2022 03:05 pm ET
IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results
ICESECRET study interim findings presented at the Urological Association Conference in Eilat, IsraelProSense was found to be a safe and effective treatment method for renal lesions smaller than 5 cm in patients not suitable for kidney-preserving surgeryProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countriesCAESAREA, Israel, Dec. 19, 2022 /PRNewswire/ --- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys
Dec 06, 2022 07:00 am ET
Dec 05, 2022 06:00 am ET
IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights
Conference call is scheduled for 8:00 a.m. EST today with guest speaker Dr. Hania Bednarski, oncoplastic breast surgeon and cryoablation specialist skilled in using the ProSense System Regulatory filings submitted in the United States for ProSense for treatment in breast cancer Achievement of Medicare coverage code for case-by-case reimbursement Regulatory approval received in Brazil for ProSense cryoprobes and introducers for treatment in several indicationsRegulatory filings submitted in Canada and Vietnam for ProSense for treatment in numerous indications CAESAREA, Israel, Dec. 5, 2022 /P
Nov 30, 2022 07:00 am ET
IceCure's ProSense Featured in Poster Presentation at Radiological Society of North America's 2022 Annual Meeting
Dr. Kenneth Tomkovich Presents: "To Freeze Or Not To Freeze? That Is The Question: Cryoablation For The Treatment Of Breast Cancer"Increasing interest among breast and interventional radiologists in performing breast tumor cryoablationCAESAREA, Israel, Nov. 30, 2022 /PRNewswire/ --  IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced that ProSense is featured in a poster presentation titled "To Freeze Or Not To Freeze? That Is The Question
Nov 29, 2022 07:00 am ET
TIME CHANGE: IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022
CAESAREA, Israel, Nov. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30, 2022 on Monday, December 5, 2022 with a press release issued at 7:00 a.m. EST.
Nov 28, 2022 07:00 am ET
IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022
CAESAREA, Israel, Nov. 28, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30, 2022 on Monday, December 5, 2022 with a press release issued at 7:30 a.m. EST. IceCure's management team, joined by Dr. Hania Bednarski, oncoplastic breast surgeon and cryoablation specialist at Sere
Nov 08, 2022 07:00 am ET
IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures
Receives assignment to a Medicare Payment Group for hospital outpatient paymentMarks CMS's first payment assignment for cryoablation of breast cancer Code and preliminary payment amount for facility fee will be effective January 1, 2023, which together may lead to a coverage policy subject to receipt of FDA marketing authorization  Filed De Novo Classification with FDA for breast cancer marketing authorization in October 2022 CAESAREA, Israel, Nov. 8, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablati
Oct 26, 2022 08:00 am ET
IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month
ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back to their lives
Oct 19, 2022 08:00 am ET
IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery
43,000 cases estimated annually in the U.S. alone for indication in initial filing representing an estimated $80 million annual addressable market  65,000 cases estimated annually in the U.S. for broader indication Company intends to file based on FDA's guidance, reflecting the full ICE3 study population after ICE3 5-year follow-ups are completed for all patients in 2024 To date, the Ipsilateral Breast Tumor Recurrence (IBTR) rate for the entire study population is 3.09%Submission data include IBTR as the primary endpointCAESAREA, Israel, Oct. 19, 2022 /PRNewswire/ -- IceCure Medical Ltd. (N
Oct 11, 2022 08:00 am ET
IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil
Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil ProSense Cryoablation System approval in Brazil is pending$6.6 million in expected sales during the five years following full regulatory approval, per distribution agreementCAESAREA, Israel, Oct. 11, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its ProSense Cryoprobes and I
Aug 29, 2022 08:00 am ET
IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®
Company is rapidly expanding its global regulatory and commercial reach
Aug 15, 2022 04:01 pm ET
IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights
Conference call scheduled for 4:30 p.m. EDT today Exclusive distribution agreement signed with Shanghai Medtronic Zhikang Medical Devices Co. Ltd. for IceSense3 cryoablation systems with minimum purchase target of $3.5 million in first 3 years of the contract; first systems to be delivered in 2022In Q2, IceCure participated in 10 conferences and events to feature ProSense® including the American Society of Breast Surgeons annual meeting where IceCure's ICE3 trial clinical publication was presented as one of the "Best Papers of 2021" CAESAREA, Israel, Aug. 15, 2022 /PRNewswire/ -- IceCure Med
Aug 09, 2022 08:00 am ET
IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022
CAESAREA, Israel, Aug. 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the six months ended June 30, 2022 on Monday, August 15, 2022 with a press release issued at 4:00 p.m. EDT and will conduct a conference call that will take place that day at 4:30 p.m. EDT. The conference call will be hosted by IceCure
Jul 25, 2022 08:00 am ET
IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors
Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other tumors
Jun 15, 2022 08:00 am ET
IceCure's ProSense® Featured at SIR 2022 Annual Meeting in Breast Cancer Cryoablation Categorical Course
Strong interest in ProSense from potential customers and distributors spurred by categorical course and Shanghai Medtronic deal
Jun 13, 2022 08:00 am ET
IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China
Shanghai Medtronic to exclusively distribute IceSense3 cryoablation systems with a minimum purchase target of $3.5 million in the first 3 years of the contract  First IceSense3 systems to be delivered in 2022 CAESAREA, Israel, June 13, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System (marketed under the brand name IceSense3 in China), that destroys tumors by freezing as an alternative to surgical tumor removal today announced that its wholly-owned subsidiary, IceCu
Jun 09, 2022 08:00 am ET
IceCure Medical's ProSense® Cryoablation System Submitted for Regulatory Approval in Brazil
Regulatory filing submitted by KTRFIOS, IceCure's distributor in BrazilFiling includes breast and other cancers, benign tumors, palliative intervention, and other indicationsCAESAREA, Israel, June 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced that KTRFIOS IMPORTACAO E EXPORTACAO LTDA., IceCure's distributor in Brazil ("KTRFIOS"), has submitted a regulat
May 18, 2022 07:00 am ET
IceCure Medical Reports First Quarter 2022 Financial Results and Operational Highlights
Conference call scheduled for 8:30 am ET today hosted by management with guest Dr. Richard FineIncreased commercial activity in the U.S. and globally with several new ProSense® System installations during Q1 Resumption of in-person medical conferences and practitioner site visits boosts ProSense® hands-on demos, trainings, and sales opportunities  American Society of Breast Surgeons' former President presented IceCure's ICE3 trial clinical publication in her speech "Best Papers of 2021" at ASBrS following a thorough literature review of thousands of breast cancer articles published yearlyCAE
May 11, 2022 02:09 pm ET
IceCure Medical to Report Q1 2022 Results and Conduct Conference Call May 18, 2022
CAESAREA, Israel, May 11, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal ("ProSense"), today announced it will report its business and financial results for the first quarter ended March 31, 2022 on Wednesday, May 18, 2022 with a press release issued at 7:00 am ET. IceCure's management team, joined by Dr. Richard Fine, will host a conference call that morning at 8:30 am ET.
Apr 27, 2022 09:00 am ET
IceCure Medical Presents ICE3 Breast Cancer Trial Interim Data, Hosts Cryoablation Symposium & Conducts Hands-On ProSense® Training Sessions at the European Conference on Interventional Oncology
CAESAREA, Israel, April 27, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it hosted three key ProSense® System events at the European Conference on Interventional Oncology (ECIO) from April 24 to 27, 2022 in Vienna, Austria.
Jan 31, 2022 07:00 am ET
IceCure Medical Announces Preliminary Unaudited 2021 Year-End Financial Results
CAESAREA, Israel, Jan. 31, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced preliminary unaudited year-end financial results for the twelve months ended December 31, 2021.
Jan 05, 2022 07:00 am ET
IceCure Medical CEO Issues Letter to Shareholders
CAESAREA, Israel, Jan. 5, 2022 /PRNewswire/ --  IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today released the following letter to shareholders from its Chief Executive Officer, Eyal Shamir.
Dec 13, 2021 04:09 pm ET
IceCure Medical Ltd. Closes $17 Million Underwritten Public Offering and Partial Exercise of Over-Allotment Option
CAESAREA, Israel, Dec. 13, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the closing of its underwritten public offering of 3,892,152 shares of the Company's ordinary shares, inclusive of 578,325 shares offered pursuant to the underwriters' over-allotment option, at a price to the public of $3.45 per share, before underwriting discounts and commissions, and to certain
Dec 09, 2021 07:30 am ET
IceCure Medical Ltd. Announces Pricing of $15 Million Underwritten Public Offering
CAESAREA, Israel, Dec. 9, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (the "Company" or "IceCure"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the pricing of an underwritten public offering of 3,313,827 shares of the Company's ordinary shares (the "Ordinary Shares") at a price to the public of $3.45 per share, before underwriting discounts and commissions, and to certain investors in lieu of Ordinary Shares, pre-funded warrants to purchas
Oct 20, 2021 08:35 am ET
Thinking about buying stock in Sesen Bio, FinVolution Group, Valneva SE, Cyclerion Therapeutics, or Icecure Medical?
NEW YORK, Oct. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SESN, FINV, VALN, CYCN, and ICCM.
Oct 12, 2021 08:00 am ET
IceCure Medical Announces Updated Regulatory Strategy in China for the IceSense3® System to Treat Cancerous Tumors with Cryoablation
CAESAREA, Israel, Oct. 12, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced the advancement of its regulatory strategy in China with the submission of an amendment to the registration certificate for the IceSense3® system, which was granted by China's National Medical Products Administration ("NMPA"). The amendment, if approved, will allow the Company to sell its disposable IceSense3 Cryoprobes for commercial procedur